| News
GETEC acquires Infrapark Baselland
20.11.2018
The energy services provider GETEC is acquiring Infrapark Baselland AG and its activities from the chemicals company Clariant. GETEC also intends to acquire Novartis’s facilities in the neighbouring Schweizerhalle, thus boosting the site’s attractiveness.
Clariant, Infrapark Baselland AG and GETEC recently signed the agreement for the planned sale to GETEC, announced a statement from Infrapark Baselland AG. According to the terms, the transaction will be completed by the end of the year.
GETEC is also acquiring Novartis’s production and infrastructure facilities in the Schweizerhalle site. The move signals the creation of a “new and diversified industrial park with economic significance for the entire region”, writes the statement.
“We are very pleased to have found in GETEC an owner for Infrapark Baselland AG, which has the necessary know-how to operate, integrate and develop industrial parks. I am convinced that this step will give the Schweizerhalle location and thus the employees an attractive future perspective,” commented Oliver Kinkel, head of region Europe at Clariant, in the statement.
With GETEC as operator, Schweizerhalle will gain competitiveness as a chemical life science park and create better growth opportunities “for new companies operating on the site”. A first company has already signed to move into the Schweizerhalle in the coming year: the chemicals specialist Van Baerle. Following the sale, Clariant will also remain as a tenant in Infrapark Baselland.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Clinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...
Read MoreKUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read MoreInvestors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read MoreBSI integrating AI from Parashift in banking software
Parashift, the specialist in the area of smart document processing on the basis of Artificial Intelligence (AI), has entered into...
Read MoreUptownBasel joins IBM Quantum Network
UptownBasel is partnering with IBM. The emerging competence center for Industry 4.0 will provide its partners with the IBM Quantum...
Read MoreSouth Korean pharma firms show interest in the Basel Area
Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...
Read More